SANNZ Stock Overview
A specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Santhera Pharmaceuticals Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 8.25 |
| 52 Week High | CHF 11.30 |
| 52 Week Low | CHF 7.69 |
| Beta | 0.13 |
| 11 Month Change | -9.74% |
| 3 Month Change | -8.84% |
| 1 Year Change | -10.62% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 291.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 1.6% | -5.2% | 0.8% |
| 1Y | -10.6% | -20.1% | 6.6% |
Return vs Industry: SANNZ exceeded the UK Biotechs industry which returned -20.1% over the past year.
Return vs Market: SANNZ underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| SANNZ volatility | |
|---|---|
| SANNZ Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SANNZ has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SANNZ's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 45 | Dario Eklund | www.santhera.com |
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases.
Santhera Pharmaceuticals Holding AG Fundamentals Summary
| SANNZ fundamental statistics | |
|---|---|
| Market cap | CHF 95.64m |
| Earnings (TTM) | CHF 62.86m |
| Revenue (TTM) | CHF 113.59m |
1.5x
P/E Ratio0.8x
P/S RatioIs SANNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 113.59m |
| Cost of Revenue | CHF 6.52m |
| Gross Profit | CHF 107.07m |
| Other Expenses | CHF 44.21m |
| Earnings | CHF 62.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.19 |
| Gross Margin | 94.26% |
| Net Profit Margin | 55.34% |
| Debt/Equity Ratio | 49.2% |
How did SANNZ perform over the long term?
See historical performance and comparison